First, transcript abundance. Use bulk RNA-seq and ideally single-cell RNA-seq. Bulk RNA-seq gives stable cohort-level
expression estimates; single-cell RNA-seq is needed because this model is sensitive to cell-to-cell variation around a
threshold, and the paper itself points out that expression noise can obscure the underlying landscape. In cancer, that
issue is bigger, not smaller, because of intratumoral heterogeneity.

Second, protein abundance. You need quantitative proteomics, not just RNA. The model is about effective functional
abundance, and RNA is only an imperfect proxy. Use mass spectrometry proteomics, and for signaling genes,
phosphoproteomics as well. For receptors, kinases, cell-cycle proteins, DNA repair factors, and apoptosis regulators,
protein-level calibration matters more than transcript-level calibration.

Third, gene dosage and structural regulation. Use copy-number alteration data, mutation data, and ideally
allele-specific expression. In cancer, expression can be driven by amplification, deletion, mutation, enhancer
hijacking, promoter methylation, or post-transcriptional control. If you skip CNV and mutation, your inferred
“overabundance” term will be confounded.

Fourth, direct fitness or dependency measurements. This is the critical piece. You need CRISPR knockout, CRISPRi, or
RNAi dependency data to estimate where the effective threshold sits for each gene in each cancer context. The paper’s
logic depends on a threshold-like drop in fitness below a critical abundance. In cancer, that threshold has to be
inferred from perturbation-response data, not assumed. Best sources are gene-effect scores, dose-response depletion
experiments, and time-resolved viability/proliferation readouts across cell lines or organoids.

Fifth, burden and toxicity of overexpression. The paper argues that overabundance is shaped not just by expression, but
also by toxicity and regulation. In cancer, that means you need data on the cost of forced overexpression or
amplification. Useful data types are ORF overexpression screens, inducible expression systems, growth-rate measurements
after ectopic expression, unfolded protein response / proteotoxic stress markers, ROS, ATP burden, and
ribosome/proteostasis stress readouts.

Sixth, regulatory-state data. Since regulation changes overabundance in the paper, you need data that tell you whether
the gene is tightly controlled or constitutively active. Use ATAC-seq, ChIP-seq or CUT&RUN for key TFs, promoter
methylation, miRNA data, and RNA stability / translation efficiency data if available. This is especially important for
oncogenes and lineage factors.

Seventh, microenvironment context. A cancer model calibrated in ideal culture will be incomplete. Thresholds shift under
hypoxia, low glucose, immune pressure, drug treatment, and stromal signaling. So if the model is intended for tumors
rather than just cell lines, include matched conditions such as hypoxia RNA-seq/proteomics, drug-perturbation screens,
coculture assays, and spatial transcriptomics if you want tumor-region-specific calibration.

Eighth, longitudinal or perturbation time series. Static omics are weak for calibration of a threshold model. You want
time-resolved data after knockdown, inhibition, stress, or nutrient limitation so you can estimate how abundance changes
before fitness collapses. That gives you the threshold region rather than just endpoint correlations.